All In Biotech

Free tool

FAERS Monitor: Kalydeco

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203188 or its brand name (Kalydeco, Ivacaftor). Reports on generic versions are filed under their own applications.

Reports

7,984

Serious

5,947

74% of reports

Hospitalization

4,426

Death reported

327

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hospitalisation1,384
  • infective pulmonary exacerbation of cystic fibrosis611
  • pneumonia271
  • infection257
  • lower respiratory tract infection255
  • malaise255
  • death229
  • cough225
  • cystic fibrosis220
  • headache197
  • nasopharyngitis171
  • influenza162
  • dyspnoea145
  • pulmonary function test decreased138
  • off label use126

Reports by year received

View as table
YearReports
2012174
2013129
2014383
2015523
2016271
2017403
2018558
20191,037
2020896
2021593
2022651
2023598
2024750
2025695
2026323

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,175 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal611333.0307.0179,302
cystic fibrosisSignal220109.095.422,503
pulmonary function test decreasedSignal13885.772.511,111
hospitalisationSignal1,38423.922.830,342
lower respiratory tract infectionSignal25514.913.23,269
infectionSignal2574.74.2745
influenzaSignal1623.83.3337
nasopharyngitisSignal1712.42.1146
pneumoniaSignal2712.22.0180
coughSignal2252.11.9133
malaise2551.51.448
headache1970.80.77
death2290.70.630
dyspnoea1450.70.623
off label use1260.40.3133

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.